Меню
Идёт набор NCT06200831

Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases

Без фазы С лечением Colorectal Cancer Colorectal Neoplasms Malignant Liver Metastasis Colon Cancer Liver Metastases

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Staged resection, Simultaneous resection.
Кому может быть актуально
Состояния в реестре: Colorectal Cancer, Colorectal Neoplasms Malignant, Liver Metastasis Colon Cancer, Liver Metastases. Базовые параметры: 18 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Норвегия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases - A Multicentre Randomized Controlled Trial

Обзор

The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and/or ablation (RFA/MWA) at time of evaluation.

Подробное описание

Colorectal cancer (CRC) represents the second most common cause of cancer and cancer death in Norway, and the incidence is increasing (Cancer in Norway, 2021, Cancer Registry of Norway). The liver is the most common site of metastasis from CRC. More than 4500 individuals are diagnosed with CRC in Norway each year, and approximately 20% of patients present with liver metastases at time of diagnosis (synchronous metastases). Resection of both the primary tumor and liver metastases is considered the only curative treatment, and has been shown to improve long-term survival, and is considered standard of care. However, the optimal timing of surgical resection of synchronous liver metastases in relation to the primary tumor is not well defined. Traditionally, staged resection has been preferred (i.e., resection of the primary tumour and liver metastases on separate admissions with a period of recovery between the two operations), whereas simultaneous resection is appealing (i.e., resection of both primary and metastases in one operative session). Despite a lack of randomized controlled trials comparing these two surgical approaches, the number of simultaneous resections has increased at several institutions. The evolvement of both liver and colorectal surgery in the last decades has led to reduced complications, making simultaneous resections more feasible. Previous retrospective cohort studies and meta-analyses suggest that simultaneous and staged approach carry similar postoperative complication and perioperative mortality rates as well as long-term survival. A recently published prospective observational study on staged or simultaneous surgery, reported similar outcomes in selected patients. To date, there is only one published randomized controlled trial which was aborted after inclusion of half of the sample size, after an accrual time of 10 years18. Due to lack of evidence, the majority of surgical societies worldwide still treats this patient group with staged resections, resulting in two hospital admissions, two rounds of general anaesthesia and surgery, and finally two episodes of postoperative recovery and rehabilitation. If this trial demonstrates that simultaneous surgery is safe, feasible, and cost-effective, it will potentially have a practice-changing impact worldwide.

Вмешательства

  • Процедура Staged resection
    Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
  • Процедура Simultaneous resection
    In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.

Первичные конечные точки

  • Comprehensive Complication Index, CCI [Срок оценки: 90 days]
Вторичные конечные точки (5)
  • Health Economics [Срок оценки: 1 year]
  • Overall survival [Срок оценки: 3 and 5 years]
  • Clavien Dindo Complications [Срок оценки: 90 days]
  • Quality of Life: EQ-5D [Срок оценки: Pre-operative, 30-days, 90-days, 6 months, 12 months]
  • Quality of Life: EORTC QLQ-30 [Срок оценки: Pre-operative, 30-days, 90-days, 6 months, 12 months]

Критерии участия

Критерии включения

  • Age 18-80 years old.
  • Both CRC and liver metastases in situ at time of evaluation.
  • Resectable primary tumor in the colon or upper rectum.
  • Less than 5 liver metastases, evaluated by the multidisciplinary tumor board meeting as possible to treat with surgical resection and/or ablation (RFA/MWA).

Критерии исключения

  • Unresectable primary tumor.
  • Locally advanced primary tumor (T4).
  • Primary tumor in the lower rectum with indication for abdominoperineal resection.
  • Acute or imminent bowel obstruction.
  • Perforation or major bleeding from the primary tumor.
  • Pre-treatment of the primary tumor with a colon stent.
  • Liver resection requiring resection of more than 2 adjacent segments (Couinaud).
  • Liver metastases planned treated with irreversible electroporation (IRE).
  • Non-resectable lung metastases.
  • Metastases outside of liver (besides resectable lung metastases).
  • Eastern Cooperative Oncology Group (ECOG) Performance status ≥ 3.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Норвегия · 1 центр
  • Oslo University Hospital — Oslo

Публикации

  • Kleive D, Aas E, Angelsen JH, Bringeland EA, Nesbakken A, Nymo LS, Schultz JK, Soreide K, Yaqub S. Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps. Oncol Ther. 2021 Jun;9(1):111-120. doi: 10.1007/s40487-021-00148-2. Epub 2021 Mar 23. PMID 33759076
  • Siriwardena AK, Serrablo A, Fretland AA, Wigmore SJ, Ramia-Angel JM, Malik HZ, Stattner S, Soreide K, Zmora O, Meijerink M, Kartalis N, Lesurtel M, Verhoef C, Balakrishnan A, Gruenberger T, Jonas E, Devar J, Jamdar S, Jones R, Hilal MA, Andersson B, Boudjema K, Mullamitha S, Stassen L, Dasari BVM, Frampton AE, Aldrighetti L, Pellino G, Buchwald P, Gurses B, Wasserberg N, Gruenberger B, Spiers HVM, PMID 37471055
  • Yaqub S, Margonis GA, Soreide K. Staged or Simultaneous Surgery for Colon or Rectal Cancer with Synchronous Liver Metastases: Implications for Study Design and Clinical Endpoints. Cancers (Basel). 2023 Apr 6;15(7):2177. doi: 10.3390/cancers15072177. PMID 37046837

Идентификаторы

NCT: NCT06200831 · 201644

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗